Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis.

Abstract

BACKGROUND:

Alefacept (anti-CD2) biological therapy selectively targets effector memory T cells (Tem) in psoriasis vulgaris, a model Type 1 autoimmune disease.

METHODS:

Circulating leukocytes were phenotyped in patients receiving alefacept for moderate to severe psoriasis.

RESULTS:

In all patients, this treatment caused a preferential decrease in effector memory T cells (CCR7- CD45RA-) (mean 63% reduction) for both CD4+ and CD8+ Tem, while central memory T cells (Tcm) (CCR7+CD45RA-) were less affected, and naïve T cells (CCR7+CD45RA+) were relatively spared. Circulating CD8+ effector T cells and Type 1 T cells (IFN-gamma-producing) were also significantly reduced.

CONCLUSION:

Alefacept causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis.

• Authors: Francesca Chamian, Shao-Lee Lin, Edmund Lee, Toyoko Kikuchi, Patricia Gilleaudeau, Mary Sullivan-Whalen, Irma Cardinale, Artemis Khatcherian, Inna Novitskaya, Knut M Wittkowski, James G Krueger, Michelle A Lowes
• Journal: Journal of translational medicine (J Transl Med) Vol. 5 Pg. 27 (Jun 07 2007) ISSN: 1479-5876 [Electronic] England
• PMID: 17555598 (Publication Type: Clinical Trial, Journal Article, Research Support, N.I.H., Extramural)

Chemical References

• Antigens, CD
• Antigens, Differentiation, T-Lymphocyte
• CD2 Antigens
• CD69 antigen
• Dermatologic Agents
• Lectins, C-Type
• Recombinant Fusion Proteins
• Alefacept

Topics

• Adult
• Aged
• Alefacept
• Antigens, CD (immunology)
• Antigens, Differentiation, T-Lymphocyte (immunology)
• CD2 Antigens (immunology)
• Cell Movement (drug effects)
• Dermatologic Agents (administration & dosage, therapeutic use)
• Female
• Humans
• Immunologic Memory (drug effects)
• Lectins, C-Type
• Lymphocyte Activation (drug effects, immunology)
• Lymphocyte Count
• Lymphocyte Subsets (drug effects, pathology)
• Male
• Middle Aged
• Phenotype
• Psoriasis (drug therapy, immunology, pathology)
• Recombinant Fusion Proteins (administration & dosage, pharmacology, therapeutic use)
• T-Lymphocytes (drug effects, immunology, pathology)